Every Form 4 that Halliburton Company (HAL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HAL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HAL filings page.
Halliburton Company executive Sarah I. Rubenfeld, SVP & Chief Accounting Officer, reported a new stock award in company shares. On 01/02/2026 she acquired 5,610 shares of Halliburton common stock under the Halliburton Company Stock and Incentive Plan, based on a New York Stock Exchange closing price of $29.60 on the grant date. The plan allows shares to be surrendered back to Halliburton to cover tax withholding obligations.
After this grant, she beneficially owns 73,310.422 Halliburton shares, which includes 15.422 shares purchased through the Employee Stock Purchase Plan for the period ending September 30, 2025. She also holds options to buy 9,688 shares at an exercise price of $49.61 exercisable from January 2, 2018 until January 2, 2028, and options to buy 7,994 shares at $55.68 exercisable from January 3, 2017 until January 3, 2027.
Halliburton Company executive insider activity: The President - Eastern Hemisphere of Halliburton reported equity transactions effective 01/02/2026. The executive received 41,156 shares of common stock under the Halliburton Company Stock and Incentive Plan, with the grant referenced to a closing share price of $29.60. The filing also shows the vesting of 3,552 restricted stock units from an award granted in January 2025, which converted into common shares.
After these transactions, the executive beneficially owned 70,991 shares of Halliburton common stock directly. The report lists remaining derivative holdings, including 14,204 restricted stock units and several stock option awards with exercise prices ranging from $24.68 to $49.61 and expirations between 2026 and 2030. Each restricted stock unit represents the right to receive one share of common stock as it vests in equal annual installments.
Halliburton Company disclosed an insider equity transaction by its Executive Vice President & Chief Financial Officer. On January 2, 2026, the officer acquired 37,548 shares of common stock as an award under the Halliburton Company Stock and Incentive Plan at the New York Stock Exchange closing price of $29.60 per share on the grant date. Following this award, the officer beneficially owned 159,719.623 shares, which includes 166.852 shares accumulated through dividend reinvestment as of December 31, 2025. The filing also notes that a stock option covering 9,534 shares with a $34.48 exercise price expired on January 4, 2026, while other stock options remain outstanding.
Halliburton Company reported that an executive serving as EVP, Secretary and Chief Legal Officer acquired additional common stock in the company. On January 2, 2026, the executive received 34,968 shares of Halliburton common stock as an award under the Halliburton Company Stock and Incentive Plan, which allows shares to be surrendered to cover tax withholding. The closing price of Halliburton common stock on the grant date was $29.60 per share.
Following this grant, the executive directly beneficially owns 368,496.49 shares of Halliburton common stock. In addition, the executive holds an option to buy 54,348 shares of common stock at an exercise price of $23.57 per share, which is exercisable and expires on January 15, 2030.
Halliburton Company’s Director, President & CEO reported a new stock award. On January 2, 2026, the executive acquired 133,458 shares of common stock at a value based on the New York Stock Exchange closing price of $29.60 per share. The shares were granted under the Halliburton Company Stock and Incentive Plan, which allows shares to be surrendered back to the company to cover tax withholding obligations.
Following this grant, the executive beneficially owns 1,131,090.02 shares of Halliburton common stock directly. The filing also lists existing stock options, including options to buy 171,200 shares at $31.44 expiring on December 5, 2028, 128,500 shares at $43.38 expiring on December 6, 2027, and 69,500 shares at $53.54 expiring on December 7, 2026.
Halliburton Company director reports equity awards and deferred stock units. A Halliburton Co (HAL) director filed details of equity-based compensation, including stock equivalent units and restricted stock units that convert to common stock on a one-for-one basis.
On 12/30/2025, the director acquired 1,211.885 stock equivalent units under the Halliburton Company Directors' Deferred Compensation Plan, which are settled in common stock after service as a director ends. These units, along with prior accruals, totaled 12,940.639 derivative securities beneficially owned directly after the transaction.
The filing also lists several restricted stock unit awards, each representing the right to receive one share of common stock. Awards include 7,485 units from 12/2025, 7,485 units from 12/2024, 6,264.53 units from 12/2023, 5,070.76 units from 03/2023, and 4,052.66 units, all held directly. The restricted stock units generally vest in one year on the first anniversary of the award, with shares delivered either upon vesting or following cessation as a director if deferral was elected.
Halliburton Company reported director equity activity involving restricted stock units and common shares on December 5, 2025. A block of 6,092 shares of common stock was acquired at a price of $0 following the exercise of derivative securities, increasing the director's directly held common stock to 21,375 shares.
In the derivative table, 7,485 restricted stock units granted in December 2025 were acquired, each representing one share of common stock, with 7,485 derivative securities beneficially owned afterward. Another 6,092 restricted stock units from a December 5, 2024 grant were converted, leaving no units remaining from that grant. The restricted stock units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if elected, after the director ceases service.
Halliburton Company director reports new equity award in a Form 4 filing. On 12/05/2025, the director received 7,485 restricted stock units for Halliburton common stock. Each restricted stock unit represents the right to receive one share of common stock.
The 2025 restricted stock units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if the director elected deferral, after leaving the board. Following this award, the director holds 18,768.867 shares of Halliburton common stock directly, as well as derivative holdings that include 7,485 restricted stock units from 2025 and 6,226.77 restricted stock units from a 2024 award.
Halliburton Company director reported a new equity award consisting of 7,485 restricted stock units as of 12/05/2025. Each restricted stock unit represents the right to receive one share of Halliburton common stock and generally vests in one year on the first anniversary of the award, with delivery either at vesting or, if elected, after the director leaves the board.
The filing also lists previously granted restricted stock units tied to Halliburton common stock in amounts of 6,226.77, 5,040.19 and 4,028.23 shares, along with 11,728.754 stock equivalent units accrued under the company’s Directors’ Deferred Compensation Plan, which convert into common stock on a one-for-one basis following the director’s board service.
Halliburton Company reported a routine equity compensation update for one of its directors. On December 5, 2025, the director acquired 6,092 shares of common stock at $0, following the vesting of previously granted restricted stock units from a December 5, 2024 award. After this transaction, the director directly owned 87,496 shares of Halliburton common stock.
The director was also granted a new award of 7,485 restricted stock units dated December 2025, each representing the right to receive one share of common stock. These units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if the director elected deferral, after service as a director ends.
Halliburton Company director Form 4 filing reports an equity award. On 12/05/2025, the director received 7,485 restricted stock units, each representing the right to receive one share of Halliburton common stock.
The restricted stock units vest in one year on the first anniversary of the award. Shares will be delivered either when the units vest or, if the director has elected to defer receipt, after the director ceases serving on the board. The award is reported as a derivative security held directly by the director at an exercise price of $0.
Halliburton director reports restricted stock activity and share holdings. A Halliburton Co. director filed a Form 4 reporting equity compensation-related transactions on 12/05/2025. The director acquired 7,485 restricted stock units at an exercise price of $0, each representing one share of Halliburton common stock. On the same date, 6,092 restricted stock units granted on December 5, 2024 vested, resulting in the acquisition of 6,092 shares of common stock at $0.
Following these transactions, the director beneficially owns 580,688.509 shares of Halliburton common stock directly and 7,485 restricted stock units that each convert into one share. The filing notes that these restricted stock units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if elected, after the director leaves the board.
Halliburton Company reported an equity award to one of its directors on a Form 4. On 12/05/2025, the director acquired 7,485 restricted stock units (RSUs) tied to Halliburton common stock at an exercise price of $0, classified as an acquisition transaction. Each RSU represents a right to receive one share of common stock.
The RSUs from the 12/2025 grant vest in one year on the first anniversary of the award, with shares delivered either at vesting or, if the director elected deferral, after ceasing service as a director. The filing also shows previously granted RSUs from 12/2024 and 12/2023, with 6,226.77 and 5,040.19 underlying shares, respectively, including dividend equivalent units through September 30, 2025. Following the reported transactions, the RSUs are held in direct ownership.
Halliburton Company director reported equity awards and vesting activity dated 12/05/2025. The director acquired 7,485 restricted stock units (RSUs) labeled as "12/2025 Restricted Stock Units," each representing a right to receive one share of common stock. On the same date, 6,092 RSUs granted December 5, 2024 vested, resulting in the acquisition of 6,092 shares of common stock at a stated price of $0.
After these transactions, the director beneficially owned 16,643 shares of common stock directly. Additional RSU positions remain outstanding from prior annual grants, including blocks labeled as "12/2022" and "12/2021 Restricted Stock Units" that incorporate dividend equivalent units through September 30, 2025. The RSUs generally vest in one year on the first anniversary of the award, with shares delivered upon vesting or after service as a director if deferral was elected.
Halliburton Company director Form 4 details equity changes. On 12/05/2025, the director reported a disposition of 16,000 shares of Halliburton common stock. The filing also shows a new grant of 12/2025 restricted stock units covering 7,485 shares of common stock, reported as derivative securities.
Each restricted stock unit represents a right to receive one share of Halliburton common stock. The 12/2025 units vest in one year on the first anniversary of the award, with shares delivered upon vesting or, if the director elected to defer, after ceasing board service. The director also lists multiple outstanding restricted stock unit awards from 2016 through 2024, including dividend equivalent units through September 30, 2025.
Halliburton Company reported a new equity award for one of its directors. On December 5, 2025, the director acquired 7,485 restricted stock units (RSUs) tied to Halliburton common stock at a stated price of $0 per unit. Each RSU represents the right to receive one share of Halliburton common stock.
The 12/2025 RSUs vest in one year on the first anniversary of the award, with shares delivered either at vesting or, if the director elected deferral, after they cease serving as a director. The filing also lists multiple prior RSU grants and 19,310.229 stock equivalent units that convert into common stock on a one-for-one basis and are settled in shares following cessation as a director.
Halliburton Company director equity update: A Halliburton Co (HAL) director reported receiving 7,485 restricted stock units on 12/05/2025 at a price of $0, reflecting an equity award rather than an open‑market purchase. Each restricted stock unit represents the right to receive one share of Halliburton common stock.
The newly granted 12/2025 restricted stock units vest in one year on the first anniversary of the award, with shares delivered either upon vesting or, if the director elected to defer receipt, after cessation as a director. The director also beneficially owns multiple prior‑year restricted stock unit awards and stock equivalent units, including 6,226.77 units from 12/2024, 13,438.45 units from 12/2020, and 41,930.748 stock equivalent units accrued under the Directors' Deferred Compensation Plan, all convertible into common stock on a one‑for‑one basis, generally following cessation as a director.
Halliburton Company’s director, president and CEO reported routine changes in ownership tied to equity compensation. On December 4, 2025, 20,966 shares of common stock were transferred to Halliburton to cover federal tax withholding when restricted stock vested from a grant originally made on December 2, 2020. The reference price for the tax withholding was $26.91 per share, the NYSE closing price on December 2, 2025.
After this transaction, the insider beneficially owns 997,632.02 shares of Halliburton common stock, including 901.551 shares purchased through the company’s employee stock purchase plan for the period ending March 31, 2025. The filing also lists several outstanding stock options with exercise prices between $31.44 and $53.54, and notes that a 99,200-share option grant that was due to expire on December 2, 2025 has now expired.
Halliburton Company executive share transaction disclosed
A Halliburton Company officer, identified as President - Western Hemisphere, reported a routine share transaction dated December 4, 2025. The filing shows that 7,383 shares of common stock were transferred back to Halliburton to cover federal tax withholding triggered by the vesting of previously granted stock under the company’s Stock and Incentive Plan. The closing price of Halliburton common stock on the New York Stock Exchange on December 2, 2025, when the stock vested, was $26.91.
After this tax-related share transfer, the officer beneficially owned 444,990.607 shares of Halliburton common stock. The report also lists several outstanding stock options to buy Halliburton common stock with exercise prices between $27.14 and $55.68 and expiration dates ranging from January 4, 2026 to December 20, 2028, indicating existing long-term equity incentives.
Halliburton Company executive Sarah I. Rubenfeld, EVP Administration & CHRO, reported routine equity transactions involving Halliburton common stock. On December 4, 2025, 5,840 shares of common stock were transferred to Halliburton to cover federal tax withholding when restricted stock vested under the Stock and Incentive Plan. The vesting relates to stock granted on December 2, 2020, using the New York Stock Exchange closing price of $26.91 on December 2, 2025 for tax purposes. After these tax-related shares were withheld, she beneficially owned 484,831.685 shares directly, including 929.708 shares acquired through the Employee Stock Purchase Plan.
The filing also lists several outstanding stock options, including options to buy 51,100, 34,300, and 30,500 shares at exercise prices of $31.44, $43.38, and $53.54, respectively, with expirations in 2028, 2027, and 2026. A separate option for 44,500 shares at an exercise price of $38.95 expired unexercised on December 2, 2025.
Halliburton Company officer reports tax-related share transfer and option expiration. A Senior Vice President and Treasurer of Halliburton Company reported a Form 4 transaction dated December 4, 2025. The filing shows 658 shares of common stock were transferred to Halliburton to cover federal tax withholding when restrictions lapsed on stock granted under the company’s Stock and Incentive Plan, based on a New York Stock Exchange closing price of $26.91 on December 2, 2025. After this transaction, the officer beneficially owns 77,126 shares of common stock directly. The report also lists several outstanding stock options and notes that an option covering 8,300 shares, originally granted on December 2, 2015, expired on December 2, 2025.
Halliburton Company reported insider stock activity by its EVP, Secretary and Chief Legal Officer. On December 4, 2025, the officer transferred 5,746 shares of common stock to Halliburton at $26.91 per share to cover federal tax withholding tied to restricted stock that vested on December 2, 2025 from a grant made on December 2, 2020. On December 5, 2025, the officer sold 8,854 shares of common stock at $27.89 per share under a pre-arranged Rule 10b5‑1 trading plan adopted on August 13, 2025. After these transactions, the officer directly owned 333,528.49 shares of Halliburton common stock and held an option to buy 54,348 shares at an exercise price of $23.57 per share, exercisable until January 15, 2030.
Halliburton Company executive reports routine tax-related share transfer. The company’s EVP & Chief Financial Officer filed a Form 4 showing that on December 4, 2025, 5,691 shares of Halliburton common stock were transferred to the company to cover federal tax withholding when previously granted restricted stock vested. The shares relate to stock granted on December 2, 2020, which vested on December 2, 2025, when Halliburton’s stock closed at $26.91 on the New York Stock Exchange.
After this transaction, the executive beneficially owns 122,004.771 shares, including 594.394 shares accumulated through dividend reinvestment as of September 30, 2025. The filing also lists multiple stock options to buy Halliburton common stock, with exercise prices ranging from $31.44 to $53.54 and expiration dates between January 4, 2026 and December 5, 2028.
Halliburton (HAL) insider activity: A company officer (President - Western Hemisphere) reported selling 160,000 shares of common stock on 11/12/2025 at $27.77 per share (transaction code S), pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
Following the sale, the reporting person beneficially owned 452,373.607 shares. This figure includes 901.551 shares purchased through the Employee Stock Purchase Plan for the period ending March 31, 2025, and 10,193.461 shares accumulated via dividend reinvestment as of September 30, 2025. The filer also lists outstanding stock options, including 43,924 options at a $27.14 exercise price expiring 12/20/2028 and 28,604 options at $34.48 expiring 01/04/2026.
Maurice S. Smith, a Halliburton (HAL) director, reported acquisitions and existing holdings under director compensation plans. The filing shows 1,372.04 stock equivalent units acquired on 09/29/2025 under the Halliburton Directors' Deferred Compensation Plan, with a portion attributable to quarterly dividends and fees based on closing prices of $24.44 on September 24, 2025 and $25.00 on September 29, 2025. The report also lists restricted stock units vesting after one year from grant dates in 12/2024, 12/2023 and 03/2023, and totals of 11,728.754 shares and additional stock equivalent balances of 6,226.77, 5,040.19 and 4,028.23 respectively as reported through September 30, 2025. The units convert one-for-one to common stock and may be settled upon cessation as a director.